NCT05907408

Omics Techniques in Fatty Liver Disease

Name: Clinical Trial NCT05907408
Creator: Universidade Federal do Rio de Janeiro
Keywords: Non-Alcoholic Fatty Liver Disease, clinical trial, Brazil

Precision Medicine in Fatty Liver Disease: How to Identify the Patient Who Develops Steatohepatitis Using Omics Techniques

Universidade Federal do Rio de Janeiro·ClinicalTrials.govNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Non-Alcoholic Fatty Liver Disease
Study type: Observational

Sponsor & location

Primary sponsor: Universidade Federal do Rio de Janeiro
Location: Rio de Janeiro, Brazil

Timeline & enrollment

Phase: N/A
Start date: Jul 01, 2023
End date: Dec 31, 2023
Enrollment: 10 participants

Primary outcome

Steatosis, without fibrosis or inflammation,Steatohepatitis, with fibrosis

Summary

Nonalcoholic steatohepatitis (NASH) is the most common cause of chronic liver disease in Western countries and one of the leading causes of liver transplantation in the world. Its spectrum ranges from simple steatosis to decompensated cirrhosis, resulting from progressive fibrosis due to inflammation and cellular injury. The reasons why patients with the same degree of steatosis have different evolutions are not sufficiently known. The objective of this project is to identify biomarkers that predict disease progression, using omics techniques, which can serve to develop new therapeutic strategies.

ICD-10 classifications

Alcoholic fatty liverAlcoholic liver disease, unspecifiedAlcoholic liver diseaseLiver disease, unspecifiedAlcoholic cirrhosis of liver

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT05907408
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT05907408 through Pure Global AI's free database. This phase not specified trial is sponsored by Universidade Federal do Rio de Janeiro and is currently Not yet recruiting. The study focuses on Non-Alcoholic Fatty Liver Disease. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.